Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and...
Vous n'êtes pas connecté
Tirzepatide may reduce hospitalizations, improve symptoms, and decrease death risks in heart failure patients, offering new hope for those with preserved ejection fraction.
Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and...
Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and...
PLAINSBORO, N.J., Aug. 30, 2024 /PRNewswire/ -- Today, The Lancet published a new pooled, participant-level analysis of patients with heart failure...
PLAINSBORO, N.J., Aug. 30, 2024 /PRNewswire/ -- Today, The Lancet published a new pooled, participant-level analysis of patients with heart failure...
PLAINSBORO, N.J., Sept. 3, 2024. The Lancet has published a new pooled, participant-level analysis of patients with heart failure with mildly reduced...
MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients.
Up to a million people in the UK live with heart failure, a condition that reduces quality of life and increases the risk of hospital admission.
Cryoballoon (CB) ablation is as effective at reducing recurrences of atrial fibrillation (AF) and atrial tachycardia (AT) at 1-year, when compared to...
Cryoballoon (CB) ablation is as effective at reducing recurrences of atrial fibrillation (AF) and atrial tachycardia (AT) at 1-year, when compared to...
Sulthiame may help prevent patients’ breathing from temporarily stopping, international research suggests